Management of Diabetic Foot Ulcer (DFU)

Severe diabetic foot infection with necrosis, neuropathy, and hindfoot deformity - Bailey & Love's Surgery, p.628

Pathophysiology: The Triad

• Peripheral neuropathy - loss of protective sensation (LOPS), muscle atrophy, claw/hammer toe deformities, autonomic neuropathy causing dry skin and fissures
• Peripheral arterial disease (PAD) - macrovascular and microvascular insufficiency; ~15-20% of DFUs lead to lower extremity amputation (LEA); ~85% of all amputations are preceded by DFU
• Immune dysfunction - impaired neutrophil function, poor tissue healing, susceptibility to polymicrobial infection

Step 1: Classification

• 1-year risk of major amputation
• Theoretical benefit/requirement of revascularization

Step 2: Comprehensive Evaluation

Wound Assessment

• Debride overlying callus to expose true wound extent
• Probe with cotton swab back for depth and bone penetration (probe-to-bone test)
• 3-view plain X-ray of the foot - evaluates for osteomyelitis, Charcot deformity, structural abnormalities

Neuropathy Assessment

• 10-g monofilament (primary tool) + at least one of: pinprick, temperature, vibration, or proprioception
• Assess for structural deformity (claw/hammer toe, bunion, callus)

Vascular Assessment

• Palpation of pulses (unreliable in diabetics due to medial calcinosis/calcification)
• Ankle-brachial index (ABI) - can be falsely elevated due to vessel calcification
• Toe-brachial index (TBI) and toe pressure - more reliable in diabetics
• Transcutaneous oxygen (TcPO2) - useful for wound healing potential
• Duplex ultrasound, CTA, or MRA for detailed vascular mapping before revascularization

Infection Workup

• Blood: CBC, CRP, ESR, blood cultures if systemically unwell (markers may be normal/mildly elevated)
• Superficial ulcer swabs are unreliable for deep infection - deep tissue culture or bone biopsy preferred
• MRI is the most sensitive modality for osteomyelitis (detects before plain X-ray changes appear)
• Probe-to-bone test + elevated inflammatory markers + abnormal X-ray = osteomyelitis confirmed

Step 3: Management Pillars

A. Glycemic Optimization

• Tight glycemic control is essential throughout management
• Target HbA1c <7-8% in most patients; reduces infection risk and improves healing
• Insulin often required acutely even in type 2 DM when infected/hospitalized

B. Pressure Offloading

• Single most important local treatment for neuropathic plantar ulcers
• Total contact cast (TCC) - gold standard offloading device; redistributes plantar pressure
• Removable cast walker (RCW)/aircast boot - useful but compliance-dependent
• Felted foam padding, therapeutic footwear, crutches/wheelchair as alternatives
• Structural deformities causing recurrent ulceration may require surgical correction (exostectomy, rebalancing procedures)

C. Local Wound Care

Debridement

• Sharp surgical debridement at every visit removes non-viable tissue, callus, fibrinous slough
• Exposes wound base for accurate grading and improved healing
• Enzymatic or autolytic debridement for wounds not amenable to sharp debridement

Dressings

• Maintain moist wound environment without maceration
• Saline-moistened gauze - simple, widely available
• Hydrocolloid/hydrogel - for clean granulating wounds
• Alginate/foam - for highly exudative wounds
• Silver-impregnated dressings - for mildly infected/colonized wounds
• Iodine-based dressings - antimicrobial for biofilm-heavy wounds
• Avoid wet-to-dry dressings (damages granulation tissue)

Advanced Wound Therapies (for non-healing wounds)

• Negative pressure wound therapy (NPWT / VAC) - promotes granulation, reduces edema; meta-analysis (PMID 39241769, 2024) confirms efficacy in RCTs
• Bioengineered skin substitutes (e.g., Apligraf, Dermagraft) - for chronic non-healing ulcers
• Platelet-rich plasma (PRP)
• Hyperbaric oxygen therapy (HBO) - last resort for wounds with inadequate perfusion (osteomyelitis, gangrene, non-revascularizable ischemia)
• Growth factors (PDGF - becaplermin)

D. Infection Management

Microbiology

Antibiotic Principles

• Mild infection (skin/subcutaneous only): oral antibiotics targeting S. aureus and Streptococci (e.g., amoxicillin-clavulanate, cefalexin)
• Moderate infection: broader spectrum oral or IV (e.g., co-amoxiclav IV, or fluoroquinolone + metronidazole)
• Severe infection: IV broad-spectrum (e.g., piperacillin-tazobactam, or carbapenem + vancomycin for MRSA risk)
• Always de-escalate based on culture results
• Duration: 1-2 weeks for soft tissue only; 4-6+ weeks for osteomyelitis

Surgical Management of Infection

• Required for: collections/abscesses, necrotic tissue, extensive osteomyelitis
• Debridement must remove all infected material; excess bone resected to allow tension-free skin closure
• Distinguish superficial osteitis (loss of soft tissue cover, responds to local measures) from deep osteomyelitis (requires bone debridement)
• In severe peripheral neuropathy, a below-knee amputation in an area with intact sensation may be preferable to repeated forefoot surgeries

E. Vascular Management (Revascularization)

• Mandatory full vascular assessment in all patients with poor pulses or grade 1+ ischemia
• Endovascular intervention (PTA, stenting) - first-line for suitable lesions; lower perioperative risk
• Open surgical bypass - preferred for long-segment occlusions, heavily calcified vessels not crossable endovascularly; use single-segment saphenous vein; translocated (not reversed) for size match to tibial vessels; arm vein is an acceptable alternative
• Both approaches show equivalent amputation-free survival in experienced centers
• Perform debridement for source control first in acutely infected wounds before angiography; in subacute infection, revascularize before debridement to prevent ischemia-mediated necrosis

Step 4: Osteomyelitis - Specific Management

Step 5: Amputation

• Not a failure of management but sometimes the correct option
• Indications: uncontrollable infection, extensive tissue loss, non-reconstructable ischemia, failed revascularization
• Wound healing is unreliable post-amputation in diabetics - ensure adequate perfusion at planned level
• Toe/ray amputation - for isolated digit disease
• Transmetatarsal amputation - for forefoot involvement
• Below-knee amputation - preferable to above-knee when vascular supply allows; better rehabilitation potential
• Bone resection must be adequate to remove all infected material; tension-free skin closure is essential

Step 6: Multidisciplinary Team and Prevention

MDT Approach

• Diabetologist / endocrinologist (glycemic control)
• Vascular surgeon (revascularization)
• Orthopedic/podiatric surgeon (debridement, reconstruction)
• Infectious disease specialist (antibiotic stewardship)
• Orthotist/podiatrist (offloading, footwear)
• Wound care nurse
• Rehabilitation team

Prevention of Recurrence

• Custom therapeutic footwear and regular podiatry
• Daily foot inspection by patient
• Strict glycemic control
• Smoking cessation
• Correction of structural deformities
• Periodic monofilament screening and vascular monitoring
• Patient education

Summary Algorithm

DFU Diagnosed
    ↓
Classify (WIfI grade)
    ↓
Assess Triad: Neuropathy | Ischemia | Infection
    ↓
All Patients:
  • Glycemic control
  • Offloading (TCC preferred)
  • Debridement + appropriate dressing
    ↓
Infected? → Antibiotics (targeted); Surgery if collection/necrosis/osteomyelitis
    ↓
Ischemic? → Vascular imaging → Endovascular or open bypass
    ↓
Non-healing at 4-6 weeks? → Advanced therapies (NPWT, skin substitute, HBO)
    ↓
Unsalvageable limb → Amputation at appropriate level
    ↓
MDT follow-up + Prevention

• Current Surgical Therapy 14e (Kavousi, Hicks, Abularrage), pp. 1185-1192
• Bailey and Love's Short Practice of Surgery 28th Ed, pp. 627-628
• Dalmedico MM et al. Effectiveness of NPWT in DFU: systematic review and meta-analysis. Wounds. 2024 Aug. PMID: 39241769